MNPR
Monopar Therapeutics
$99.27
+4.05 (+4.25%)
At close · Jul 8
Market Cap
$700.05M
Shares
6,699,062
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2025
Net Income
-$13.72M
+12%
FY2025
Operating Cash Flow
-$12.2M
-90.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $0 | $0 | $0 | — | — | — | $0 | $0 | $0 | $0 | |
| $365.97K | — | — | $429.04K | $21.24K | $24.02K | $81.9K | $98.89K | $103.22K | $48.26K | $7232 | |
| $11.75M | $9.9M | $13.01M | $5.6M | $7.59M | $6.49M | $4.07M | $1.97M | $1.77M | $935.32K | $280.36K | |
| $6.96M | $6.8M | $3.16M | $3.23M | $2.95M | $2.63M | $2.44M | $2.36M | $1.56M | $1.17M | $912.47K | |
| $18.71M | $16.7M | $16.16M | $8.83M | $10.54M | $9.13M | $6.51M | $4.32M | $3.33M | $16.6M | $1.19M | |
| -$18.71M | -$16.7M | -$16.16M | -$8.83M | -$10.54M | -$9.13M | -$6.51M | -$4.32M | -$3.33M | -$16.6M | -$1.19M | |
| $3.72M | $2.99M | $404.02K | $429.04K | — | — | — | — | — | — | — | |
| — | -$13.72M | -$15.59M | -$8.4M | — | — | — | — | -$3.3M | -$16.55M | — | |
| — | $800 | $800 | $800 | $800 | $0 | $18.36K | $0 | -$70.82K | -$3558 | $800 | |
| -$14.98M | -$13.72M | -$15.59M | -$8.4M | -$10.52M | -$9.1M | -$6.3M | -$4.22M | -$3.23M | -$16.55M | -$1.19M | |
| -$14.92M | -$13.62M | -$15.54M | -$8.43M | -$10.5M | -$9.1M | -$6.3M | -$4.23M | -$3.23M | -$16.55M | — | |
| USD/shares | — | -$1.85 | -$4.11 | -$3.04 | -$4.15 | — | — | — | — | — | — |
| shares | — | 7.41M | 3.79M | 2.76M | 2.54M | 2.49M | 2.19M | 1.86M | 1.86M | 1.76M | — |
| shares | — | — | — | — | — | 2.49M | 2.19M | 1.86M | 1.86M | 1.76M | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2024–FY2025: $35M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
—
Biotechnology median 7.68×